AUA

Qmax was also significantly improved, with a baseline of 7.7 mL/sec compared with 13.2 mL/sec at 4 years.

Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."

The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in three-fourths of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, according to findings from the phase 3 BOND-003 trial.

Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association Annual Meeting.

"Our research focused on the outcomes at 6 months, [and we] were looking at disease recurrence and hernia occurrence," says Jennifer Nguyen.

"About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels," says Praveen Thumbikat, DVM, PhD.

"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.

"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.

"We have to be intentional in order to design our trials so that we have a better participation of those groups," says Larissa V. Rodriguez, MD.

"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.

"What we found is that AI+ score using continuous variables had the highest predictive ability of all oncologic outcomes that were measured," says Nour Abdallah, MD.

"A lot to be done in terms of moving PARP inhibitors earlier. Is that safe? Where do we get the most bang for our buck? And does the therapy have to be indefinite?" says Ashley E. Ross, MD, PhD.

"When it comes to BPH therapy, we've seen a lot of innovation when it comes to the therapeutics; the diagnostics have been a tiny bit behind," says Bilal Chughtai, MD.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

"In summary, it was safe and effective. There [were] no serious adverse events...and the vast majority of patients received no anesthesia with very similar results to shock wave lithotripsy,” said Ben H. Chew, MD, MSc, FRCSC.

"Because we don't have calibration data on Black, or Hispanic, or Asian men in many of these risk tools, we don't know the impact of these tools as screening tests," says Adam Murphy, MD, MBA, MSCI.

"The most important thing for transgender women and their health care providers to remember is that prostate cancer screening shouldn’t be neglected," said Stephen J. Freedland, MD.

Treatment with the Optilume BPH System resulted in significant, immediate symptomatic and functional improvements in patients with BPH, according to 12-month data from the PINNACLE study.

“The ARAMIS Rollover Study extended the duration of darolutamide treatment and demonstrated the long-term safety of darolutamide in patients with [nonmetastatic CRPC],” said Neal D. Shore, MD.

“The combination of sintilimab and axitinib had a manageable safety profile and achieved a promising tumor response rate in patient with advanced FH-deficient RCC,” said Xingming Zhang.

Data from the retrospective DEAR study linked darolutamide to lower rates of discontinuation and progression to metastatic disease vs enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.

“This is a pivotal phase 3 trial that I think is going to be practice changing to the urology community,” said Brian Shuch, MD.

"The hazard ratio was 0.42, which is a 58% reduction of an MFS event in favor of the combination arm," says Neal D. Shore, MD, FACS.

Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.

"PRP does not seem to be effective in treating men with erectile dysfunction, at least as a monotherapy,” said Ranjith Ramasamy, MD.

“Zenflow is a novel minimally invasive surgical therapy that delivers a nitinol device into the prostatic urethra displacing the lateral lobes for improved urinary flow,” explained Dean Elterman, MD.

"We found that in the 25-patient pilot study that we did, that the accuracy was about 98% of what a standard sequencer would offer," says Deepak Kapoor, MD.

Beyond demonstrating clinical activity, pembrolizumab was safe and tolerable in this patient population.

“These results further support nivolumab as a standard of care for high-risk MIUC and MIBC after radical resection,” said Matthew Milowsky, MD.